title: [Correlation between baseline plasma D-dimer levels and prognosis in patients with non-smal cell lung cancer].
abstract: OBJECTIVE
  To investigate the correlation of baseline plasma D-dimer levels and clinicopathological features and tumor VEGF expression in non-small cell lung cancer(NSCLC) patients, and to evaluate the value of D-dimer in predicting survival time.
  
  
  METHODS
  A retrospective review of the clinicopathological data of 290 NSCLC patients confirmed pathologically in Tianjin Cancer Hospital from July 2007 to April 2009 was performed. The correlations between plasma baseline D-dimer levels and clinicopathological characteristics and progonosis were analyzed.
  
  
  RESULTS
  For 290 NSCLC patients with low ( ≤ 0.3 µg/ml) and high (>0.3 µg/ml) D-dimer levels, the median survival times were 54.0 months and 46.2 months, respectively (P < 0.05), and for the patients with stages I, II, IIIA, IIIB and IV NSCLC, the median survival times were 58.1, 40.6, 26.7 and 23.5 months, respectively (P < 0.05). In the operable patients (stages I, II and IIIa) with low and high D-dimer levels, the median progression-free survivals (PFS) were 35.0 and 11.0 months, respectively (P < 0.05). Furthermore, the median PFSs were 57.2 months and 19.6 months, respectively, in these operable patients without and with lymph node metastasis (P < 0.05).
  
  
  CONCLUSIONS
  High levels of baseline plasma D-dimer may indicate advanced disease stage, larger tumor size, lymph node metastasis and stronger tumor angiongenesis to some extent, and may be useful in prediction of survival time in NSCLC patients of different stages.
authors.affiliation: Department of Thoracic Oncology, Tianjin Medical University Tumor Institute and Hospital, National Clinical Research Center of Cancer Tianjin Lung Cancer Diagnosis and Treatment Center, Tianjin 300060, China.
authors.forename: Ping-ping
authors.initials: PP
authors.lastname: Zhang
authors.affiliation: Department of Thoracic Oncology, Tianjin Medical University Tumor Institute and Hospital, National Clinical Research Center of Cancer Tianjin Lung Cancer Diagnosis and Treatment Center, Tianjin 300060, China.
authors.forename: Jun-wei
authors.initials: JW
authors.lastname: Sun
authors.affiliation: Department of Thoracic Oncology, Tianjin Medical University Tumor Institute and Hospital, National Clinical Research Center of Cancer Tianjin Lung Cancer Diagnosis and Treatment Center, Tianjin 300060, China.
authors.forename: Jiu-qin
authors.initials: JQ
authors.lastname: Lu
authors.affiliation: Department of Thoracic Oncology, Tianjin Medical University Tumor Institute and Hospital, National Clinical Research Center of Cancer Tianjin Lung Cancer Diagnosis and Treatment Center, Tianjin 300060, China.
authors.forename: Liang-liang
authors.initials: LL
authors.lastname: Ma
authors.affiliation: Department of Thoracic Oncology, Tianjin Medical University Tumor Institute and Hospital, National Clinical Research Center of Cancer Tianjin Lung Cancer Diagnosis and Treatment Center, Tianjin 300060, China. Email: likai5@medmail.com.cn.
authors.forename: Kai
authors.initials: K
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel; D011013:Pneumonectomy / Q000379:methods; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use; D047368:Tumor Burden; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D043823:Taxoids; D042461:Vascular Endothelial Growth Factor A; C036309:fibrin fragment D; D017239:Paclitaxel; D002945:Cisplatin